Sexual health

Yellow or Green Discharge From the Penis: What It Means and When to See a Clinician

Save

Abnormal penile discharge — cloudy, yellow, green, or white fluid other than urine, semen, or pre-ejaculate — is most often caused by a sexually transmitted infection such as gonorrhea, chlamydia, or non-gonococcal urethritis. Antibiotic resistance in gonorrhea makes laboratory testing important; a clinician visit within a few days is appropriate. Uncomplicated gonorrhea is usually treated with a single ceftriaxone injection, dosed by body weight.

Last updated: July 2026History

Talk to a clinician

A primary-care clinician

Gale can help you find one in your state and request a visit.

Find care →

What counts as abnormal penile discharge?

A small amount of clear fluid with arousal (pre-ejaculatory fluid) is normal. What is not normal and warrants a clinical visit 1:

  • Yellow, green, or gray-colored discharge
  • Cloudy or opaque discharge
  • Thick or pus-like (purulent) discharge
  • Discharge that occurs without sexual arousal
  • Any discharge accompanied by burning, pain, or unusual smell

If you are uncertain whether what you are noticing is normal, a clinician can assess it quickly.

One thing worth knowing before you call: routine STI screening guidance does not settle this question. The USPSTF "concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men" — an I statement — while giving a B recommendation for screening women 24 and younger 2. Screening is about people with no symptoms. Discharge is a symptom, so this is diagnostic testing, and it is indicated regardless of what the screening guidance says.

What are the common causes?

Gonorrhea is the most classically associated cause of thick yellow or green purulent penile discharge. It typically appears 1 to 14 days after exposure and may be accompanied by burning on urination. Some gonorrhea infections in the urethra cause mild or no symptoms despite the infection being present 1.

Chlamydia — the most commonly reported bacterial STI — often produces milder or thinner discharge, sometimes clear or white rather than yellow, and is frequently asymptomatic 2. However, some people with chlamydia do have visible discharge.

Trichomoniasis can produce yellowish-green, frothy discharge with a strong odor, though it is often asymptomatic in people with penises 1.

Non-gonococcal urethritis (NGU) is inflammation of the urethra not caused by gonorrhea. It can be caused by chlamydia or other organisms including Mycoplasma genitalium, which requires a specific antibiotic and is increasingly recognized as a significant cause of urethral symptoms 1.

Urinary tract infection or prostatitis is less common in people with penises than in those with vaginas, but can cause discharge-like symptoms alongside urinary burning and frequency.

For scale: "Approximately 1.8 million cases of chlamydia and more than 600,000 cases of gonorrhea were reported to the Centers for Disease Control and Prevention (CDC) in 2019" 2. Because many of these infections cause no symptoms at all 2, reported cases are only the ones that were found.

Why does early testing matter — including for antibiotic resistance?

Untreated gonorrhea can spread to the epididymis (the tube behind the testicle), causing epididymitis — testicular pain and swelling — with potential effects on fertility. Untreated chlamydia carries similar risks 1. These infections can also be passed to sexual partners who have no symptoms of their own.

Antibiotic resistance in gonorrhea is a genuine and growing concern. The 2021 CDC STI Treatment Guidelines specify a particular regimen for gonorrhea precisely because shifting resistance patterns have made older approaches unreliable 1. Self-treating with leftover antibiotics is not a safe approach — it can mask results, fail to clear the infection, and contribute to resistance.

The resistance concern has a number attached. The share of Neisseria gonorrhoeae isolates with reduced susceptibility to azithromycin "increased more than sevenfold over 5 years (from 0.6% in 2013 to 4.6% in 2018)" — which is why CDC moved in December 2020 to ceftriaxone alone for uncomplicated gonorrhea, dropping azithromycin from the routine regimen 4. The dose is weight-based: 500 mg intramuscularly for people weighing under 150 kg (300 lb), and 1 g for those weighing 150 kg or more 4. Ceftriaxone itself has held up so far — its MIC50 and MIC90 "were only one doubling dilution higher during 2014–2018, compared with the respective ceftriaxone MIC50 and MIC90 during 1992–1995" 4. That margin is exactly what leftover-antibiotic self-treatment erodes.

What happens at the appointment?

A clinician will ask about your symptoms, sexual history, and any other signs. Testing typically involves a urethral swab or first-catch urine sample sent for NAAT (nucleic acid amplification test) — the most sensitive method for gonorrhea and chlamydia 23. A broader STI panel including HIV, syphilis, and hepatitis may be offered because shared exposure routes make co-infection possible 1.

Results often return within a few days. If gonorrhea is strongly suspected based on the clinical picture, some clinicians begin treatment before results return. You will also be advised to notify recent sexual partners so they can be tested and treated — reinfection is common when partners go untreated 1.

Treatment for uncomplicated gonorrhea is short, and the dose is set by body weight: CDC recommends "Ceftriaxone 500 mg IM as a single dose for persons weighing <150 kg (300 lb)", and "For persons weighing ≥150 kg (300 lb), 1 g of IM ceftriaxone should be administered" 4. Where chlamydia has not been excluded, doxycycline 100 mg orally twice daily for 7 days is added; in pregnancy, azithromycin 1 g as a single dose is used instead 4. Two follow-up points are easy to miss: people treated for gonorrhea "should be retested 3 months after treatment," and throat gonorrhea gets a test-of-cure by culture or NAAT 7–14 days after treatment 4.

What to ask for depends on how you were exposed: a urine sample only tests the urethra, and site-specific swabs are what complete the evaluation 3:

ExposureSample to request
Insertive vaginal or anal sexFirst-catch urine, or a urethral swab 3
Receptive anal sexA rectal swab, in addition to urine 3
Oral sexA pharyngeal (throat) swab 3

NAATs can test for infection at urogenital and extragenital sites, including urine, endocervical, vaginal, male urethral, rectal, and pharyngeal 2 — the lab only tests the sites you sample, so say where you were exposed.

Common questions

Yes — both gonorrhea and chlamydia can be entirely asymptomatic in people with penises. This is why routine STI screening (not just symptom-driven testing) is important for sexually active people at elevated risk.

Yes. Avoid sex until you have your results and any infection has been treated. If you test positive, avoid sex until you and your partner(s) have both completed treatment and a follow-up confirms the infection has cleared.

For uncomplicated gonorrhea, CDC recommends a single intramuscular dose of ceftriaxone, dosed by weight — 500 mg for people weighing under 150 kg (300 lb), and 1 g for those weighing 150 kg or more. Doxycycline 100 mg orally twice a day for 7 days is added where chlamydia has not been ruled out. People treated for gonorrhea should be retested 3 months later, and throat infections get a test-of-cure 7 to 14 days after treatment.

No. Gonorrhea in particular has developed resistance to many antibiotics — isolates with reduced susceptibility to azithromycin rose from 0.6% in 2013 to 4.6% in 2018. Current treatment guidelines specify particular regimens, and the right dose depends on your weight. Using leftover or over-the-counter antibiotics is not safe — it can mask test results, fail to clear the infection, and contribute to resistance.

Yes. If you test positive for an STI, recent partners need to be notified, tested, and treated. Some health departments offer expedited partner therapy, which allows a clinician to provide treatment for a partner without requiring them to come in separately.

Less commonly, penile discharge can result from a urinary tract infection or prostatitis, especially if urinary symptoms (frequency, urgency, lower abdominal or perineal pain) are prominent and there is no recent STI exposure. A clinician can distinguish these through testing.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

A primary-care clinician

Gale can help you find one in your state and request a visit.

Find care →

When to seek care more urgently

  • —Discharge plus severe testicle or scrotal pain and swelling — can indicate epididymitis or, rarely, testicular torsion, which is a surgical emergency
  • —Fever, chills, pelvic pain, or feeling seriously unwell alongside discharge — signs of a spreading infection needing same-day evaluation
  • —Rash, joint pain, or eye redness alongside discharge — disseminated gonococcal infection (gonorrhea spreading in the bloodstream) is rare but serious

If you have sudden, severe one-sided testicular pain — especially if it came on rapidly — go to the emergency room immediately. Testicular torsion is a surgical emergency that can cause permanent damage within hours.

This article provides general health education and is not a diagnosis. Penile discharge has medical causes that require testing by a licensed clinician. Please seek care promptly rather than treating yourself or waiting to see if it resolves.

Did this answer your question?

References

  1. 1.Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. doi:10.15585/mmwr.rr7004a1 ✓Gonorrhea as leading cause of purulent penile discharge; chlamydia and trichomoniasis discharge characteristics; NGU and Mycoplasma genitalium as causes of urethritis; antibiotic resistance in gonorrhea and specific combination treatment requirements; epididymitis as a complication; partner notification and treatment; comprehensive STI panel recommendation
  2. 2.US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, et al. (2021). Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation Statement. JAMA. doi:10.1001/jama.2021.14081 ✓NAAT as the most sensitive testing method for chlamydia and gonorrhea; chlamydia's frequent asymptomatic presentation as a reason for testing even in the absence of typical discharge
  3. 3.Centers for Disease Control and Prevention (2024). Getting Tested for STIs. CDC.gov. link ✓First-catch urine and swab collection methods for NAAT testing; testing panel composition and site-specific swabs for comprehensive evaluation
  4. 4.St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, Torrone E, Weinstock H, Kersh EN, Thorpe P (2020). Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morbidity and Mortality Weekly Report 2020;69(50):1911–1916. linkCOMPLETE DOSING BLOCK: Ceftriaxone 500 mg IM as a single dose for persons weighing <150 kg (300 lb) | For persons weighing ≥150 kg (300 lb), 1 g of IM ceftriaxone should be administered. | For chlamydia co-infection where chlamydial infection has not been excluded: doxycycline 100 mg orally twice daily for 7 days | During pregnancy, azithromycin 1 g as a single dose is recommended to treat chlamydia. | Alternative regimens when ceftriaxone is unavailable (urogenital/rectal): Gentamicin 240 mg IM as a single dose plus azithromycin 2 g orally as a single dose; or Cefixime 800 mg orally as a single dose. | No reliable alternative treatments are available for pharyngeal gonorrhea. | FOLLOW-UP: for persons with pharyngeal gonorrhea, a test-of-cure is recommended, using culture or nucleic acid amplification tests 7–14 days after initial treatment | persons who have been treated for gonorrhea should be retested 3 months after treatment | RESISTANCE: the percentage of N. gonorrhoeae isolates with reduced susceptibility (MIC ≥2.0 μg/mL) increased more than sevenfold over 5 years (from 0.6% in 2013 to 4.6% in 2018) | the ceftriaxone MIC50 and MIC90 were only one doubling dilution higher during 2014–2018, compared with the respective ceftriaxone MIC50 and MIC90 during 1992–1995

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library